NovoCure Limited (NVCR) Free cash flow 2017–2026
NovoCure Limited (NVCR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$75.7MFY2026 · since FY2017: -$113.3M → -$75.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$75.7M | -9.3% |
| FY2025 | -$69.2M | +31.1% |
| FY2024 | -$100.4M | -1165.0% |
| FY2023 | $9.4M | -83.9% |
| FY2022 | $58.6M | -30.4% |
| FY2021 | $84.2M | +421.7% |
| FY2020 | $16.1M | +288.1% |
| FY2019 | -$8.6M | +78.8% |
| FY2018 | -$40.5M | +64.2% |
| FY2017 | -$113.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice